BOULDER, Colo., March 5, 2019 /PRNewswire/ -- Array
BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief
Executive Officer, Ron Squarer, will
speak at the 39th Annual Cowen Health Care Conference in
Boston. The public is welcome to
participate in the conference through a webcast on the Array
BioPharma website.
Event:
|
39th
Annual Cowen Health Care Conference
|
Presenter:
|
Ron Squarer, Chief
Executive Officer, Array BioPharma
|
Date:
|
Tuesday, March 12,
2019
|
Time:
|
12:00 p.m. Eastern
Time
|
Webcast:
|
http://wsw.com/webcast/cowen52/arry/
|
A replay of the presentation will also be accessible under the
"Investors/Investor Calendar" section of the website at
www.arraybiopharma.com.
About Array BioPharma
Array BioPharma Inc. is a
fully-integrated, biopharmaceutical company focused on the
discovery, development and commercialization of transformative and
well-tolerated targeted small molecule drugs to treat patients
afflicted with cancer and other high-burden diseases. Array markets
BRAFTOVI® (encorafenib) capsules in combination with
MEKTOVI® (binimetinib) tablets for the treatment of
patients with unresectable or metastatic melanoma with a
BRAFV600E or BRAFV600K mutation
in the United States and with
partners in other major worldwide markets. Array's lead clinical
programs, encorafenib and binimetinib, are being investigated in
over 30 clinical trials across a number of solid tumor indications,
including a Phase 3 trial in BRAF-mutant metastatic colorectal
cancer. Array's pipeline includes several additional programs being
advanced by Array or current license-holders, including the
following programs currently in registration trials: selumetinib
(partnered with AstraZeneca), LOXO-292 (partnered with Eli Lilly),
ipatasertib (partnered with Genentech), tucatinib (partnered with
Seattle Genetics) and ARRY-797. Vitrakvi®
(larotrectinib, partnered with Bayer AG) is approved in
the United States and
Ganovo® (danoprevir, partnered with Roche) is approved
in China. For more information on
Array, please visit www.arraybiopharma.com or follow
@arraybiopharma on Twitter and LinkedIn.
BRAFTOVI® and MEKTOVI® are registered
trademarks of Array BioPharma Inc. in the
United States and various other countries.
Vitrakvi® is a registered trademark of Bayer AG. All
trademarks are properties of their respective owners.
CONTACT:
Andrea N. Flynn, Ph.D.
Senior Director, Investor Relations & Corporate
Communications
(303) 381-6600
ir@arraybiopharma.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-39th-annual-cowen-health-care-conference-300807002.html
SOURCE Array BioPharma Inc.